Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04630769CT.gov FT516 and IL2 With Enoblituzumab for Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ft516 (this asset) | Masonic Cancer Center, University of Minnesota | P1 | CC · 47 |
| Carboplatin | CanariaBio Inc. | P3 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Oregovamab | CanariaBio Inc. | P3 | CCC |
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody | M.D. Anderson Cancer Center | P2 | CCC |
| Enoblituzumab | Masonic Cancer Center, University of Minnesota | P1 | CC |
| Mcy-M11 | MaxCyte, Inc. | P1 | CC |
| Cyclophosphamide | MaxCyte, Inc. | P1 | CC |
+1 more in the Fallopian Tube Adenocarcinoma cohort
Other indications for ft516
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P1 | CC · 46 |
| Ovarian Cancer | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinCanariaBio Inc.B
- IpilimumabNational Cancer Institute (NCI)CCC
- NivolumabNational Cancer Institute (NCI)CCC
- OregovamabCanariaBio Inc.CCC
- Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal AntibodyM.D. Anderson Cancer CenterCCC
Citation
Floatz Terminal. ft516 in Fallopian Tube Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ft516-fallopian-tube-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →